E-DRUG: Full Drug Trial Disclosure (2)
--------------------------------------
Dear colleagues,
As former managing editor of a leading independent clinical pharmacology
journal I would like to emphasize one of the main problems: Journals like
mine would only publish articles which are of general interest to readers
and subscribers and which have important news value. Even so, they are
expensive enterprises with low subscription rates.
However, the stuff of the majority of industry-sponsored trials tends to be
extremely boring, of low scientific value, and not worth publishing.
To my opinion it is not the primary responsibility of such quality journals
to assist in or supervise the publication of such material.
An independent internet database like the Cochrane organization would be
ideal, and it could be peer-reviewed by EMEA or FDA provided full openness
and transparency could be guaranteed. WHO can and should have a leading
role, but again financial restraints tend to be prohibitive.
Anyhow, the problem should be discussed in depth and at lenghth.
Best wishes,
Leo Offerhaus
Netherlands
offerhausl@euronet.nl
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug